• 1
    Davies L, Wolska B, Hilbich C, Multhaup G, Martins R, Simms G, Beyreuther K, Masters CL. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology. 1988; 38:168893.
  • 2
    Tysiewicz-Dudek M, Pietraszkiewicz F, Drozdzowska B. Alzheimer's disease and osteoporosis: common risk factors or one condition predisposing to the other?. Ortop Traumatol Rehabil. 2008; 10:31523.
  • 3
    Melton LJ 3rd, Beard CM, Kokmen E, Atkinson EJ, O'Fallon WM. Fracture risk in patients with Alzheimer's disease. J Am Geriatr Soc. 1994; 42:6149.
  • 4
    Tan ZS, Seshadri S, Beiser A, Zhang Y, Felson D, Hannan MT, Au R, Wolf PA, Kiel DP. Bone mineral density and the risk of Alzheimer disease. Arch Neurol. 2005; 62:10711.
  • 5
    Sato Y, Asoh T, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in elderly women with Alzheimer's disease. Bone. 1998; 23:5557.
  • 6
    Luckhaus C, Mahabadi B, Grass-Kapanke B, Janner M, Willenberg H, Jager M, Supprian T, Fehsel K. Blood biomarkers of osteoporosis in mild cognitive impairment and Alzheimer's disease. J Neural Transm. 2009; 116:90511.
  • 7
    Masters CL, Beyreuther K. Molecular neuropathology of Alzheimer's disease. Arzneimittelforschung. 1995; 45:4102.
  • 8
    Esler WP, Wolfe MS. A portrait of Alzheimer secretases—new features and familiar faces. Science. 2001; 293:144954.
  • 9
    Hardy J. A hundred years of Alzheimer's disease research. Neuron. 2006; 52:313.
  • 10
    Hardy J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimers Dis. 2006; 9:1513.
  • 11
    Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Baker M, Adamson J, Ronald J, Blangero J, Hutton M, Younkin SG. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science. 2000; 290:23034.
  • 12
    Stefani M, Liguri G. Cholesterol in Alzheimer's disease: unresolved questions. Curr Alzheimer Res. 2009; 6:1529.
  • 13
    Poirier J. Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann N Y Acad Sci. 2000; 924:8190.
  • 14
    Kaneki M. [Genomic approaches to bone and joint diseases. New insights into molecular mechanisms underlying protective effects of vitamin K on bone health]. Clin Calcium. 2008; 18:22432.
  • 15
    Sugarman MC, Kitazawa M, Baker M, Caiozzo VJ, Querfurth HW, LaFerla FM. Pathogenic accumulation of APP in fast twitch muscle of IBM patients and a transgenic model. Neurobiol Aging. 2006; 27:42332.
  • 16
    Beyreuther K, Dyrks T, Hilbich C, Monning U, Konig G, Multhaup G, Pollwein P, Masters CL. Amyloid precursor protein (APP) and beta A4 amyloid in Alzheimer's disease and Down syndrome. Prog Clin Biol Res. 1992; 379:15982.
  • 17
    Weller RO, Boche D, Nicoll JAR. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol. 2009; 118:87102.
  • 18
    Weller RO, Preston SD, Subash M, Carare RO. Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res Ther. 2009; 1:6.
  • 19
    Koistinen H, Prinjha R, Soden P, Harper A, Banner SJ, Pradat P-F, Loeffler J-P, Dingwall C. Elevated levels of amyloid precursor protein in muscle of patients with amyotrophic lateral sclerosis and a mouse model of the disease. Muscle Nerve. 2006; 34:44450.
  • 20
    Cui S, Xiong F, Hong Y, Jung JU, Li XS, Liu JZ, Yan R, Mei L, Feng X, Xiong WC. APPswe/Abeta regulation of osteoclast activation and RAGE expression in an age-dependent manner. J Bone Miner Res. 2011; 26:108498.
  • 21
    Zhou Z, Immel D, Xi CX, Bierhaus A, Feng X, Mei L, Nawroth P, Stern DM, Xiong WC. Regulation of osteoclast function and bone mass by RAGE. J Exp Med. 2006; 203:106780.
  • 22
    Zhou Z, Han JY, Xi CX, Xie JX, Feng X, Wang CY, Mei L, Xiong WC. HMGB1 regulates RANKL-induced osteoclastogenesis in a manner dependent on RAGE. J Bone Miner Res. 2008; 23:108496.
  • 23
    Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996; 274:99102.
  • 24
    Asante EA, Gowland I, Linehan JM, Mahal SP, Collinge J. Expression pattern of a mini human PrP gene promoter in transgenic mice. Neurobiol Dis. 2002; 10:17.
  • 25
    Zhang W, Yang N, Shi X-M. Regulation of mesenchymal stem cell osteogenic differentiation by glucocorticoid-induced leucine zipper (GILZ). J Biol Chem. 2008; 283:47239.
  • 26
    Huang Q, Aluise CD, Joshi G, Sultana R, St Clair DK, Markesbery WR, Butterfield DA. Potential in vivo amelioration by N-acetyl-L-cysteine of oxidative stress in brain in human double mutant APP/PS-1 knock-in mice: toward therapeutic modulation of mild cognitive impairment. J Neurosci Res. 2010; 88:261829.
  • 27
    Andreassen OA, Dedeoglu A, Klivenyi P, Beal MF, Bush AI. N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport. 2000; 11:24913.
  • 28
    Wen L, Tang FL, Hong Y, Luo SW, Wang CL, He W, Shen CY, Xiong F, Jung JU, Lee DH, Zhang QG, Brann D, Kim TW, Yan R, Mei L, Xiong WC. Vps35 haploinsufficiency increases Alzheimer's disease neuropathology. J. Cell Biol. 2011; 195:76579.
  • 29
    Ashe KH. Learning and memory in transgenic mice modeling Alzheimer's disease. Learn Mem. 2001; 8:3018.
  • 30
    German DC, Eisch AJ. Mouse models of Alzheimer's disease: insight into treatment. Rev Neurosci. 2004; 15:35369.
  • 31
    McLeod J, Curtis N, Lewis HD, Good MA, Fagan MJ, Genever PG. Gamma-secretase-dependent cleavage of amyloid precursor protein regulates osteoblast behavior. FASEB J. 2009; 23:294255.
  • 32
    Verma S, Rajaratnam JH, Denton J, Hoyland JA, Byers RJ. Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J Clin Pathol. 2002; 55:6938.
  • 33
    Justesen J, Stenderup K, Ebbesen EN, Mosekilde L, Steiniche T, Kassem M. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology. 2001; 2:16571.
  • 34
    Meunier P, Aaron J, Edouard C, Vignon G. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin Orthop Relat Res. 1971; 80:14754.
  • 35
    Sultana R, Butterfield DA. Oxidative modification of brain proteins in Alzheimer's disease: perspective on future studies based on results of redox proteomics studies. J Alzheimers Dis. 2013; 33(Suppl 1):S24351.
  • 36
    Ni X, Yang Z-J, Carter EL, Martin LJ, Koehler RC. Striatal neuroprotection from neonatal hypoxia-ischemia in piglets by antioxidant treatment with EUK-134 or edaravone. Dev Neurosci. 2011; 33:299311.
  • 37
    Pocernich CB, Butterfield DA. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim Biophys Acta. 2012; 1822:62530.
  • 38
    Imbimbo BP, Giardina GAM. γ-Secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Curr Top Med Chem. 2011; 11:155570.
  • 39
    Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA, Roberson PK, Kousteni S, O'Brien CA, Bellido T, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem. 2007; 282:2728597.
  • 40
    Manolagas SC, Parfitt AM. What old means to bone. Trends Endocrinol Metab. 2010; 21:36974.
  • 41
    Zhao G, Monier-Faugere MC, Langub MC, Geng Z, Nakayama T, Pike JW, Chernausek SD, Rosen CJ, Donahue LR, Malluche HH, Fagin JA, Clemens TL. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology. 2000; 141:267482.
  • 42
    Rached MT, Kode A, Xu L, Yoshikawa Y, Paik JH, Depinho RA, Kousteni S. FoxO1 is a positive regulator of bone formation by favoring protein synthesis and resistance to oxidative stress in osteoblasts. Cell Metab. 2010; 11:14760.
  • 43
    Ambrogini E, Almeida M, Martin-Millan M, Paik JH, Depinho RA, Han L, Goellner J, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC. FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab. 2010; 11:13646.
  • 44
    Almeida M, Ambrogini E, Han L, Manolagas SC, Jilka RL. Increased lipid oxidation causes oxidative stress, increased peroxisome proliferator-activated receptor-gamma expression, and diminished pro-osteogenic Wnt signaling in the skeleton. J Biol Chem. 2009; 284:2743848.
  • 45
    Almeida M, Han L, Martin-Millan M, O'Brien CA, Manolagas SC. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem. 2007; 282:27298305.